Wolverine Trading’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $36.5M | Buy |
65,100
+1,900
| +3% | +$1.07M | 0.03% | 401 |
|
|
2025
Q2 | $32.9M | Buy |
63,200
+8,700
| +16% | +$4.86M | 0.03% | 329 |
|
|
2025
Q1 | $34.7M | Buy |
54,500
+9,500
| +21% | +$6.53M | 0.04% | 280 |
|
|
2024
Q4 | $31.6M | Buy |
45,000
+9,800
| +28% | +$8.22M | 0.03% | 338 |
|
|
2024
Q3 | $36.7M | Buy |
35,200
+5,800
| +20% | +$6.45M | 0.04% | 268 |
|
|
2024
Q2 | $30.9M | Sell |
29,400
-8,900
| -23% | -$8.63M | 0.03% | 298 |
|
|
2024
Q1 | $36.9M | Sell |
38,300
-11,200
| -23% | -$10.6M | 0.04% | 257 |
|
|
2023
Q4 | $43.5M | Buy |
49,500
+22,200
| +81% | +$18.3M | 0.05% | 244 |
|
|
2023
Q3 | $22.5M | Buy |
27,300
+1,800
| +7% | +$1.41M | 0.02% | 342 |
|
|
2023
Q2 | $18.1M | Buy |
+25,500
| New | +$19.7M | 0.02% | 383 |
|
|
2023
Q1 | – | Sell |
-89,100
| Closed | -$64.3M | – | 4815 |
|
|
2022
Q4 | $64.3M | Buy |
89,100
+72,000
| +421% | +$53.1M | 0.1% | 156 |
|
|
2022
Q3 | $11.8M | Buy |
17,100
+8,500
| +99% | +$5.35M | 0.02% | 497 |
|
|
2022
Q2 | $5.14M | Sell |
8,600
-2,200
| -20% | -$1.43M | 0.01% | 801 |
|
|
2022
Q1 | $7.48M | Sell |
10,800
-30,200
| -74% | -$19.1M | 0.01% | 844 |
|
|
2021
Q4 | $26.3M | Buy |
41,000
+7,800
| +23% | +$4.8M | 0.03% | 391 |
|
|
2021
Q3 | $20.1M | Sell |
33,200
-6,900
| -17% | -$4.28M | 0.02% | 530 |
|
|
2021
Q2 | $21.9M | Buy |
40,100
+9,500
| +31% | +$4.81M | 0.03% | 385 |
|
|
2021
Q1 | $14.4M | Sell |
30,600
-27,800
| -48% | -$13.5M | 0.02% | 530 |
|
|
2020
Q4 | $27.9M | Buy |
58,400
+15,900
| +37% | +$8.58M | 0.04% | 295 |
|
|
2020
Q3 | $24.4M | Sell |
42,500
-2,000
| -4% | -$1.21M | 0.06% | 244 |
|
|
2020
Q2 | $27.2M | Buy |
+44,500
| New | +$25.3M | 0.07% | 178 |
|
|
2020
Q1 | – | Sell |
-89,600
| Closed | -$33.5M | – | 5147 |
|
|
2019
Q4 | $33.5M | Buy |
89,600
+13,000
| +17% | +$4.37M | 0.08% | 184 |
|
|
2019
Q3 | $20.9M | Buy |
+76,600
| New | +$22.7M | 0.06% | 269 |
|
|
2019
Q1 | – | Sell |
-64,800
| Closed | -$23.5M | – | 5160 |
|
|
2018
Q4 | $23.5M | Buy |
64,800
+4,100
| +7% | +$1.5M | 0.07% | 210 |
|
|
2018
Q3 | $24.5M | Sell |
60,700
-2,900
| -5% | -$1.1M | 0.05% | 244 |
|
|
2018
Q2 | $21.9M | Hold |
63,600
| – | – | 0.05% | 225 |
|
|
2018
Q1 | $21.9M | Sell |
63,600
-17,900
| -22% | -$6.23M | 0.05% | 225 |
|
|
2017
Q4 | $30.6M | Sell |
81,500
-14,900
| -15% | -$6.03M | 0.11% | 150 |
|
|
2017
Q3 | $43.1M | Buy |
+96,400
| New | +$45.9M | 0.16% | 98 |
|
|
2017
Q2 | – | Sell |
-64,100
| Closed | -$24.8M | – | 4852 |
|
|
2017
Q1 | $24.8M | Buy |
64,100
+19,700
| +44% | +$7.3M | 0.14% | 139 |
|
|
2016
Q4 | $16.3M | Buy |
44,400
+14,400
| +48% | +$5.48M | 0.08% | 256 |
|
|
2016
Q3 | $12.2M | Sell |
30,000
-11,100
| -27% | -$4.45M | 0.06% | 376 |
|
|
2016
Q2 | $14.3M | Buy |
+41,100
| New | +$15.8M | 0.08% | 240 |
|
Other funds holding REGN
Wolverine Trading's REGN Position: Q3 2025 in Review
Wolverine Trading increased its Regeneron Pharmaceuticals (REGN) stake by 54% in Q3 2025, buying an estimated $5.98M and bringing the position to 30,161 shares worth $16.9M. The position accounts for 0.01% of the portfolio, ranked #664.
Wolverine Trading first reported a position in REGN in Q4 2016 and has held it in 24 quarters since. The position peaked at $39.8M in Q4 2022. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.
- Wolverine Trading held 30,161 shares of Regeneron Pharmaceuticals worth $16.9M as of Q3 2025.
- Wolverine Trading bought 10,583 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $5.98M.
- Regeneron Pharmaceuticals made up 0.01% of Wolverine Trading's portfolio in Q3 2025, its #664 holding.
- Wolverine Trading first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 24 quarters since.
- Wolverine Trading's Regeneron Pharmaceuticals position peaked at $39.8M in Q4 2022.
- 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.